New drug cocktail targets Hard-to-Treat cancers

NCT ID NCT07650825

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are to check safety and find the right dose, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: OVV-01 (a drug given into a vein and directly into tumors) and AK112 (another drug given into a vein)
What this could lead to: If it works, this could point toward a new combination treatment for advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) and small (30 people) trial focused on safety and dosing, not on proving the treatment works. The drugs may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences

Hebei, Langfang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.